

Global Journal of Clinical Medicine and Medical Research [GJCMMR]
ISSN: 2583-987X (Online)
Abbreviated key title: Glob.J.Clinic.Medici.Medica.Res.
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journal-gjcmmr-home/

Liposomal Nanocarriers for NSAIDs and Phytochemicals: Potential in Anti-inflammatory Therapy

By

Sanju*[1], Dr Gaurav Kumar Soni[1]
[1]Research Scholar, [1]Associate Professor Lords University, Alwar (Raj.), 301028 India

Article History

Received: 15/03/2025
Accepted: 27/03/2025
Published: 31/03/2025

Vol – 3 Issue – 3

PP: -29-37

Abstract

Inflammation plays a crucial role in various acute and chronic diseases, necessitating effective drug delivery systems to enhance therapeutic outcomes. Conventional anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and natural bioactive compounds, often suffer from poor solubility, low bioavailability, and systemic side effects. Liposomal nanocarriers have emerged as a promising strategy for targeted and controlled drug delivery, improving drug stability, bioavailability, and therapeutic efficacy while minimizing adverse effects. This review explores the fundamentals of liposomal drug delivery systems, their advantages in anti-inflammatory therapy, and the latest advancements in liposomal formulations of NSAIDs and natural anti-inflammatory agents such as curcumin. Furthermore, we discuss the mechanisms of drug release, pharmacokinetic improvements, and the challenges associated with liposomal drug development, including formulation stability and regulatory considerations.

Keywords: *Liposomal drug delivery, anti-inflammatory therapy, nanocarriers, NSAIDs, curcumin, controlled drug release, pharmacokinetics, targeted drug delivery, inflammation management, nanomedicine.*

1. Introduction

Inflammation is a complex biological response of the body to harmful stimuli, such as pathogens, damaged cells, or toxic compounds. It plays a crucial role in initiating the healing process but can also contribute to various diseases if left uncontrolled. The inflammatory response is typically categorized into:

Acute Inflammation: A short-term response characterized by redness, swelling, heat, and pain. It is a protective mechanism essential for eliminating harmful agents.

Chronic Inflammation: A prolonged inflammatory response that can lead to tissue damage and contribute to conditions such as rheumatoid arthritis, inflammatory bowel disease (IBD), cardiovascular diseases, and neurodegenerative disorders.

Uncontrolled inflammation is associated with severe health complications, including:

- Autoimmune Disorders: Conditions like lupus, multiple sclerosis, and rheumatoid arthritis occur when the immune system mistakenly attacks healthy tissues.
- Metabolic Disorders: Chronic inflammation is linked to obesity, diabetes, and insulin resistance.
- Neurodegenerative Diseases: Alzheimer's and Parkinson’s disease are associated with persistent neuroinflammation.
- Cancer: Long-term inflammation can promote tumor progression by inducing DNA damage and creating a favorable environment for cancer cell growth.

Challenges in Conventional Anti-inflammatory Drug Delivery

The primary approach to treating inflammation involves the use of anti-inflammatory drugs, which are classified into:

- Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Examples include ibuprofen, diclofenac, and ketorolac, which inhibit cyclooxygenase (COX) enzymes to reduce inflammation.
- Corticosteroids: Such as dexamethasone and prednisone, which suppress the immune response and inflammation.

*Corresponding Author: **Sanju**

- Biologics and Immunomodulators: These are monoclonal antibodies or cytokine inhibitors used for severe inflammatory conditions.

Despite their effectiveness, conventional anti-inflammatory drugs face several limitations:

1. Low Bioavailability: Many anti-inflammatory agents, especially natural compounds like curcumin, suffer from poor solubility and absorption, limiting their therapeutic effects.
2. Short Half-life and Frequent Dosing: NSAIDs and corticosteroids often require multiple doses per day to maintain therapeutic levels, increasing the risk of side effects.
3. Gastrointestinal and Systemic Toxicity: Prolonged use of NSAIDs can lead to gastric ulcers, kidney damage, and cardiovascular complications. Corticosteroids, when used long-term, can cause immunosuppression and metabolic disturbances.
4. Lack of Targeted Delivery: Conventional drugs do not selectively accumulate at inflammation sites, leading to systemic distribution and reduced efficacy.
5. Poor Stability and Degradation: Natural anti-inflammatory agents like curcumin and resveratrol degrade rapidly in the body, reducing their therapeutic potential.

Importance of Nanotechnology in Drug Delivery

Nanotechnology has revolutionized drug delivery by addressing the limitations of conventional formulations. Nanocarriers, ranging from 1 to 1000 nm, enhance drug solubility and bioavailability, ensuring better absorption of poorly water-soluble drugs. They enable controlled and sustained drug release, reducing dosing frequency and improving patient compliance. Surface modifications allow targeted drug delivery to inflamed tissues, minimizing systemic toxicity. Additionally, nanocarriers protect sensitive drugs like curcumin from enzymatic and environmental degradation. Advanced designs, such as pH-sensitive liposomes, further enhance site-specific drug release, making nanotechnology a powerful tool in modern pharmaceutical development.

Common types of nanocarriers used in anti-inflammatory therapy include:

- **Liposomes** (phospholipid vesicles)
- **Polymeric nanoparticles** (biodegradable polymers like PLGA)
- **Solid lipid nanoparticles** (lipid-based carriers)
- **Micelles** (amphiphilic molecules)
- **Dendrimers** (branched polymer structures)

Introduction to Liposomal Nanocarriers

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. Their structural versatility allows them to encapsulate a wide range of drugs, making them ideal for anti-inflammatory drug delivery. A conventional liposome can hold hydrophobic drugs in its lipid bilayer, hydrophilic drugs in its aqueous core, and amphiphilic drugs in either the bilayer or the core shown in Figure 1. [1,2]



Figure 1. A conventional liposome can hold hydrophobic drugs in its lipid bilayer, hydrophilic drugs in its aqueous core, and amphiphilic drugs in either the bilayer or the core.

Composition and Types of Liposomes

Liposomes can be tailored for specific therapeutic applications based on their composition and size. The key components include:

- **Phospholipids:** Form the bilayer structure (e.g., phosphatidylcholine, phosphatidylserine).
- **Cholesterol:** Enhances membrane stability and drug retention.
- **Surface Modifiers:** Polyethylene glycol (PEG) is often added to improve circulation time and prevent immune clearance.[3]

Advantages of Liposomal Drug Delivery for Anti-inflammatory Therapy

Liposomal formulations offer significant advantages over conventional anti-inflammatory drugs by enhancing drug encapsulation, improving pharmacokinetics, and enabling targeted delivery. They can carry both hydrophilic and hydrophobic drugs, increasing bioavailability and prolonging half-life, thereby reducing dosing frequency. Functionalized liposomes deliver drugs directly to inflamed tissues, minimizing off-target effects and systemic toxicity. Additionally, they protect the gastrointestinal tract from NSAID-induced damage while maintaining biocompatibility and biodegradability. Notable liposomal formulations include **ketorolac**, which enhances analgesic effects with reduced GI toxicity, **curcumin**, which improves bioavailability for inflammatory conditions like arthritis and IBD, and **diclofenac**, which provides prolonged pain relief with fewer systemic side effects.

2. Fundamentals of Liposomal Drug Delivery

Liposomal drug delivery has gained significant attention in pharmaceutical sciences due to its ability to enhance the therapeutic efficacy of various drugs, including anti-inflammatory agents. Liposomes offer a versatile platform for drug encapsulation, providing targeted and controlled drug release while reducing systemic toxicity. This section explores the structure, composition, mechanisms of drug encapsulation, types of liposomal formulations, and the advantages of liposomal drug delivery in anti-inflammatory therapy.

*Corresponding Author: **Sanju**

Structure and Composition of Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. They are widely used as nanocarriers for drug delivery due to their ability to encapsulate both hydrophilic and hydrophobic drugs.

Structural Components of Liposomes

The basic structural components of liposomes include:

- **Phospholipids:**
  - The primary building blocks of liposomes, forming bilayer membranes.
  - Examples: Phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE).
  - Amphiphilic nature allows self-assembly into bilayers in aqueous environments.
- **Cholesterol:**
  - Incorporated into the bilayer to enhance membrane stability.
  - Reduces permeability and leakage of encapsulated drugs.
- **Surface Modifiers:**
  - Polyethylene glycol (PEG) is commonly used for stealth liposomes, preventing immune clearance and prolonging circulation time.
  - Ligands (antibodies, peptides) can be added for targeted drug delivery. Schematic diagram of the structure of liposomes and the different types of liposomes based on the number and size of the layers in Figure 2.[1,2,4]



Figure 2. Schematic diagram of the structure of liposomes and the different types of liposomes based on the number and size of the layers.

Mechanisms of Drug Encapsulation in Liposomes

Liposomal formulations are designed to encapsulate different types of drugs based on their physicochemical properties:

Encapsulation of Hydrophilic Drugs

- Water-soluble drugs are enclosed within the aqueous core.
- Example: Dexamethasone phosphate (a corticosteroid).

Encapsulation of Hydrophobic Drugs

- Lipophilic drugs integrate into the lipid bilayer.
- Example: Curcumin, a natural anti-inflammatory agent with poor water solubility.

Encapsulation of Amphiphilic Drugs

- Drugs with both hydrophilic and hydrophobic properties localize at the interface of the bilayer and aqueous core.
- Example: Ketorolac, an NSAID with moderate solubility characteristics.

Methods of Drug Loading into Liposomes

- Passive Loading: Drugs are encapsulated during liposome formation.
- Active Loading (Gradient-Based Loading): Uses a pH or ion gradient to force drug entrapment, increasing drug loading efficiency and stability.

Types of Liposomal Formulations

Liposomal formulations are categorized based on composition, charge, and functionalization, influencing their drug delivery properties.

Conventional Liposomes

- Composed of natural phospholipids and cholesterol.
- Exhibit rapid clearance from circulation due to opsonization (recognition by immune cells).
- Suitable for local delivery applications.

PEGylated (Stealth) Liposomes

- Surface-modified with polyethylene glycol (PEG) to evade immune recognition.
- Prolonged circulation time enhances drug accumulation at inflammation sites.
- Example: PEGylated liposomal corticosteroids for arthritis treatment.

Cationic Liposomes

- Positively charged liposomes interact with negatively charged cell membranes, enhancing cellular uptake.
- Commonly used for gene therapy and intracellular drug delivery.
- Example: Cationic liposomal curcumin for targeted anti-inflammatory effects.

pH-Sensitive and Stimuli-Responsive Liposomes

- Designed to release drugs in response to specific conditions (pH, temperature, enzymes).
- pH-sensitive liposomes release drugs in acidic environments, such as inflamed tissues.
- Example: pH-sensitive liposomal NSAIDs for targeted inflammation therapy.

Immunoliposomes (Targeted Liposomes)

- Functionalized with antibodies or ligands for site-specific drug delivery.
- Example: Anti-ICAM-1 liposomes targeting endothelial cells in inflammatory diseases.

Advantages of Liposomal Drug Delivery for Anti-inflammatory Therapy

Liposomal drug delivery offers multiple advantages in the treatment of inflammatory diseases, improving drug efficacy and safety profiles.

*Corresponding Author: **Sanju**

Enhanced Bioavailability

- Liposomes improve the solubility of poorly water-soluble drugs like curcumin, increasing absorption and therapeutic potential.

Controlled and Sustained Drug Release

- Liposomal formulations enable prolonged drug release, reducing dosing frequency and improving patient compliance.

Targeted Drug Delivery

- Liposomes accumulate preferentially at inflamed tissues due to the enhanced permeability and retention (EPR) effect.
- Functionalized liposomes can achieve active targeting, reducing systemic side effects.

Reduced Toxicity and Side Effects

- Liposomal encapsulation protects the gastrointestinal tract from NSAID-induced ulceration and minimizes corticosteroid-related immunosuppression.

Protection of Encapsulated Drugs

- Liposomes shield drugs from enzymatic degradation, extending their therapeutic half-life.

Versatility in Drug Encapsulation

- Capable of carrying hydrophilic, hydrophobic, and amphiphilic drugs, allowing combination therapy approaches.

Improved Patient Tolerance

- Biocompatible and biodegradable liposomes reduce allergic reactions and injection-site irritations. [5,6]

3. Liposomal Formulations of Anti-inflammatory Drugs

Liposomal Formulations of Anti-inflammatory Drugs

Liposomal formulations have emerged as an effective strategy to improve the therapeutic profile of anti-inflammatory drugs by enhancing their bioavailability, stability, and targeted delivery. This section explores liposomal formulations of nonsteroidal anti-inflammatory drugs (NSAIDs), natural anti-inflammatory agents, and a comparative analysis of synthetic versus natural liposomal drugs. Liposomal Formulations of NSAIDs & Natural Anti-inflammatory Agents shown in Table 1. Comparative Efficacy: Synthetic vs. Natural Liposomal Drugs as shown in Table 2. [7-10]

Table 1. Liposomal Formulations of NSAIDs & Natural Anti-inflammatory Agents

Drug	Challenges in Conventional Form	Liposomal Benefits	Applications
Liposomal Ketorolac	GI bleeding, nephrotoxicity	Prolonged action, reduced GI irritation, lower systemic toxicity	Postoperative pain, ophthalmic inflammation
Liposomal Diclofenac	GI ulcers, cardiovascular risks	Better tissue penetration, sustained release, fewer GI side effects	Rheumatoid arthritis, localized inflammation
Liposomal Ibuprofen	Gastric ulcers, kidney damage	Enhanced solubility, targeted delivery, reduced renal toxicity	Osteoarthritis, pediatric pain & fever
Liposomal Curcumin	Poor solubility, low absorption	Higher bioavailability, sustained release, increased stability	Arthritis, IBD, neuroinflammation
Liposomal Resveratrol	Rapid metabolism, low bioavailability	Improved stability, prolonged plasma half-life, targeted delivery	Cardiovascular inflammation, neuroprotection
Liposomal Quercetin	Poor absorption	Enhanced solubility, strong anti-inflammatory effects, synergistic with NSAIDs	Autoimmune diseases, skin inflammation

Table 2. Comparative Efficacy: Synthetic vs. Natural Liposomal Drugs

Aspect	Synthetic NSAIDs (Ketorolac, Diclofenac, Ibuprofen)	Natural Agents (Curcumin, Resveratrol, Quercetin)
Mechanism of Action	COX inhibition, rapid anti-inflammatory effects	Modulate multiple pathways (NF-κB, cytokines, oxidative stress)

*Corresponding Author: **Sanju**

Aspect	Synthetic NSAIDs (Ketorolac, Diclofenac, Ibuprofen)	Natural Agents (Curcumin, Resveratrol, Quercetin)
Bioavailability & PK	Faster absorption, extended half-life, possible side effects	Improved solubility, sustained effects, better safety profile
Clinical Use	Best for acute pain and inflammation	Preferred for chronic inflammation, needs further validation

4. Mechanism of Action and Pharmacokinetics

Liposomal formulations significantly enhance the therapeutic potential of anti-inflammatory drugs by altering their release profile, absorption, distribution, metabolism, and excretion (ADME). These modifications result in improved bioavailability, prolonged circulation time, and reduced toxicity. This section discusses the mechanisms of drug release from liposomes, ADME characteristics, and the advantages of liposomal formulations over conventional drugs.

Drug Release Mechanisms from Liposomes

The effectiveness of liposomal drug delivery largely depends on the mechanism by which drugs are released at the target site. Various release mechanisms ensure controlled and sustained drug action while minimizing off-target effects.

Passive Diffusion

- Hydrophilic drugs encapsulated within the aqueous core of liposomes gradually diffuse through the lipid bilayer into surrounding tissues.
- Lipophilic drugs, integrated into the lipid bilayer, diffuse directly into cell membranes.
- Example: Liposomal ibuprofen releases slowly, maintaining prolonged anti-inflammatory effects.

pH-Sensitive Release

- Some liposomes are designed to be pH-sensitive, allowing drug release in acidic environments such as inflamed tissues or tumor sites.
- Example: pH-sensitive liposomal ketorolac releases the drug efficiently in inflamed regions, increasing its local therapeutic effect.

Enzyme-Triggered Release

- Certain liposomes are engineered to degrade in response to specific enzymes present at the inflammation site.
- Example: Phospholipase A2-sensitive liposomes enhance targeted drug delivery in arthritis.

Temperature-Sensitive Release

- Heat-sensitive liposomes release drugs upon exposure to elevated temperatures at inflamed or diseased tissues.
- Example: Thermosensitive liposomal diclofenac provides controlled release at inflammatory sites.

Endocytosis and Intracellular Release

- Liposomes can be taken up by cells via endocytosis, leading to intracellular drug release when the liposome fuses with lysosomes.
- Example: Liposomal curcumin enters macrophages and modulates inflammatory signaling pathways.

Absorption, Distribution, Metabolism, and Excretion (ADME) of Liposomal Drugs

The pharmacokinetics of liposomal formulations differ from conventional drug formulations due to their nanocarrier properties, which influence absorption, tissue distribution, metabolism, and elimination.

Absorption

- Liposomal encapsulation enhances oral bioavailability by protecting drugs from enzymatic degradation in the gastrointestinal tract.
- Intravenous liposomal drugs bypass first-pass metabolism, allowing direct systemic circulation.
- Example: Liposomal resveratrol improves oral absorption and plasma concentration.

Distribution

- Liposomes extend drug circulation time by reducing renal clearance and preventing rapid metabolism.
- The enhanced permeability and retention (EPR) effect allows liposomes to accumulate preferentially in inflamed or diseased tissues.
- Stealth liposomes (PEGylated) evade immune recognition, ensuring prolonged systemic distribution.
- Example: PEGylated liposomal NSAIDs distribute preferentially to arthritic joints, reducing systemic toxicity.

Metabolism

- Liposomal drugs undergo slower metabolism compared to free drugs, increasing their half-life.
- The lipid components of liposomes may be metabolized by phospholipases in circulation.
- Example: Liposomal curcumin resists rapid hepatic metabolism, maintaining therapeutic levels for longer durations.

Excretion

- Liposomal drugs exhibit prolonged systemic retention, reducing renal clearance compared to free drugs.
- Clearance depends on particle size, lipid composition, and surface modifications.

*Corresponding Author: **Sanju**

- Large liposomes are removed via the reticuloendothelial system (RES) (liver, spleen, macrophages), whereas PEGylated liposomes show reduced RES uptake and slower elimination.
- Example: Liposomal ketorolac has a longer elimination half-life than its free form, reducing dosing frequency.

Enhanced Bioavailability and Prolonged Circulation Time
Liposomal formulations significantly improve the bioavailability and circulation time of anti-inflammatory drugs, leading to better therapeutic outcomes.

Improved Solubility and Bioavailability

- Liposomes increase the solubility of poorly water-soluble drugs, enhancing absorption.
- Example: Liposomal curcumin exhibits a 5-10 times higher bioavailability than free curcumin.

Reduced First-Pass Metabolism

- Orally administered liposomal drugs avoid extensive hepatic metabolism, increasing systemic drug levels.
- Example: Liposomal resveratrol maintains higher plasma concentrations than non-encapsulated resveratrol.

Prolonged Circulation Time

- Liposomes protect drugs from rapid degradation and excretion, extending therapeutic action.
- PEGylated liposomes exhibit longer systemic retention by avoiding immune clearance.
- Example: PEGylated liposomal diclofenac circulates for 24+ hours, compared to a few hours for its conventional form.

Targeted Drug Delivery and Reduced Toxicity

- Liposomes preferentially accumulate at inflamed sites via the EPR effect, reducing systemic side effects.
- Example: Liposomal NSAIDs minimize gastrointestinal toxicity by reducing direct gastric exposure.[11-14]

5. Advantages and Challenges of Liposomal Anti-inflammatory Therapy

Liposomal formulations of anti-inflammatory drugs enhance solubility, stability, and targeted delivery while reducing systemic toxicity. However, challenges like large-scale production, formulation stability, and regulatory hurdles limit widespread clinical use.

- Improved Solubility & Stability: Liposomes enhance drug dissolution (e.g., curcumin with 10x higher bioavailability) and protect against enzymatic degradation (e.g., ketorolac with prolonged plasma stability).
- Reduced Toxicity & Side Effects: Targeted delivery minimizes GI, renal, and cardiovascular risks (e.g., liposomal ibuprofen lowers gastric irritation, PEGylated diclofenac reduces heart risks).
- Sustained Release & Prolonged Circulation: Liposomes extend drug half-life, reducing dosing frequency (e.g., PEGylated NSAIDs remain active for 24+ hours).
- Multiple Administration Routes: Supports oral, IV, topical, and inhalation delivery for versatile treatment options.[15]

Challenges in Liposomal Anti-inflammatory Therapy
Despite the advantages, liposomal drug delivery faces several challenges, particularly in large-scale manufacturing, formulation stability, and regulatory approval.
Challenges in Large-Scale Production and Cost

The transition from laboratory-scale to commercial production of liposomal drugs is complex and costly due to:

- High Manufacturing Costs:
  - Expensive raw materials (phospholipids, cholesterol, PEGylation agents).
  - Advanced techniques required for large-scale liposome preparation (extrusion, sonication, microfluidics).
- Batch-to-Batch Variability:
  - Achieving uniform particle size, drug loading efficiency, and stability remains challenging.
- Example: Large-scale production of PEGylated liposomal diclofenac requires strict control over particle size and encapsulation efficiency, making it more expensive than traditional formulations.

Formulation Stability Issues
Liposomal formulations are prone to instability, leading to drug leakage and reduced shelf life.

- Problems with Storage and Stability:
  - Liposomes may degrade due to oxidation or hydrolysis of phospholipids.
  - Temperature-sensitive formulations require refrigeration, limiting accessibility in certain regions.
- Example: Liposomal ketorolac needs specific storage conditions to maintain its integrity and efficacy.

Drug Loading Efficiency and Release Control Ensuring high drug encapsulation efficiency and controlled release is critical but challenging.

- Low Drug Encapsulation Efficiency:
  - Some hydrophobic drugs may not fully integrate into the lipid bilayer, leading to low loading capacity.
- Premature Drug Leakage:
  - Liposomal drugs may leak before reaching the target site, reducing efficacy.
- Example: Optimizing lipid composition in liposomal curcumin formulations improves

*Corresponding Author: **Sanju**

encapsulation and reduces premature drug loss.[16,17]

6. Recent Advances and Innovations in Liposomal Drug Delivery

Liposomal drug delivery has evolved with surface modifications, stimuli-responsive systems, and co-drug encapsulation, enhancing targeting, circulation, and efficacy in anti-inflammatory therapy.

Surface Modifications for Targeted Delivery

- Ligand-Conjugated Liposomes: Functionalized with peptides or folic acid for selective binding (e.g., folic acid-liposomal NSAIDs for RA).
- Immunoliposomes: Monoclonal antibodies (mAbs) enable precise targeting (e.g., anti-TNFα liposomes for Crohn's and RA).
- PEGylation: Extends circulation time and reduces immune clearance (e.g., PEGylated ketorolac for sustained effects).

Stimuli-Responsive Smart Liposomes

- pH-Sensitive: Release drugs in inflamed acidic environments (pH-sensitive ibuprofen targets joints).
- Temperature-Sensitive: Drug release at 40–42°C (thermosensitive diclofenac for localized therapy).
- Enzyme-Triggered: Activated by MMPs or phospholipases (MMP-sensitive curcumin for arthritis).
- Redox-Responsive: ROS-triggered drug release (ROS-sensitive resveratrol for chronic inflammation).

Co-Delivery Strategies

- NSAID-Corticosteroid Liposomes: Synergistic effect (ketorolac + dexamethasone for post-surgical pain).
- Synthetic + Natural Agent Formulations: Enhanced efficacy, reduced toxicity (diclofenac + curcumin).
- Dual-Targeting Liposomes: Multi-pathway targeting (ibuprofen + TNF-α inhibitor for autoimmune disorders).[18-21]

7. Clinical Applications and Future Perspectives

Liposomal formulations of anti-inflammatory drugs have demonstrated enhanced efficacy, reduced toxicity, and improved targeting, transitioning from preclinical studies to clinical use.

Preclinical and Clinical Studies

- Arthritis: Liposomal diclofenac and ketorolac showed superior anti-inflammatory effects in RA and OA models.
- Inflammatory Bowel Disease (IBD): Liposomal curcumin improved gut healing in ulcerative colitis.
- Neuroinflammation: Liposomal resveratrol exhibited neuroprotective effects in Alzheimer's models.
- Clinical Success:
  - Exparel® (Liposomal Diclofenac): FDA-approved for post-surgical pain relief.
  - Liposomal Corticosteroids: Improved psoriasis treatment with reduced side effects.
  - Liposomal Curcumin: Enhanced pain relief in arthritis patients.[22]

Applications in Chronic Inflammatory Diseases

- Rheumatoid Arthritis & Osteoarthritis: Liposomal NSAIDs & curcumin reduce joint damage with fewer side effects.
- IBD (Crohn's & Ulcerative Colitis): Oral liposomal dexamethasone & resveratrol target gut inflammation with minimal systemic effects.
- Chronic Pain & Post-Surgical Inflammation: Liposomal bupivacaine (Exparel®) reduces opioid dependency.
- Neuroinflammation (Alzheimer's, Parkinson's): Liposomal curcumin & resveratrol cross the blood-brain barrier.
- Autoimmune Disorders (Lupus, Psoriasis, MS): Liposomal corticosteroids lower toxicity risks.[23]

Future Research and Trends

- Advanced Formulations:
  - Hybrid liposomes (lipid-polymer nanoparticles) for improved stability.
  - Stimuli-responsive liposomes (pH-sensitive, enzyme-triggered) for precise drug release.
- AI & Personalized Medicine:
  - AI predicts optimal lipid compositions for stable liposomal drugs.
  - Genetic profiling tailors personalized liposomal therapies.[24]
- Regulatory & Commercialization:
  - Liposomal resveratrol & curcumin undergoing clinical trials for arthritis & neuroinflammation.
  - FDA & EMA developing clearer nanomedicine guidelines.[25]
- Integration with Biologics & Gene Therapy:
  - Liposomal mRNA therapy targets inflammatory cytokines (e.g., IL-6, TNF-α).
  - Liposomal anti-TNFα formulations enhance autoimmune disease treatment.

Liposomal drug delivery is revolutionizing anti-inflammatory therapy, promising safer and more effective treatments for chronic conditions. [26,27]

8. Conclusion

Liposomal nanocarriers have revolutionized anti-inflammatory drug delivery by enhancing solubility, bioavailability, circulation time, and targeted therapy. Future research should focus on personalized liposomal formulations, tailoring treatments to patient-specific inflammatory

*Corresponding Author: **Sanju**

biomarker profiles. AI and computational modeling can optimize lipid composition and drug loading efficiency, improving formulation stability and efficacy. Despite promising preclinical results, large-scale clinical trials are essential to establish long-term safety, while regulatory bodies (FDA, EMA) must refine nanomedicine approval guidelines for commercialization. The integration of biologics and gene therapy, such as monoclonal antibodies and mRNA-based liposomal therapies, offers new possibilities for autoimmune and inflammatory disease management. As advancements continue, liposomal nanocarriers are poised to become a cornerstone of modern anti-inflammatory therapy, improving patient outcomes while minimizing systemic side effects.[28]

9. References

1. Gatto MS, Johnson MP, Najahi-Missaoui W. Targeted liposomal drug delivery: Overview of the current applications and challenges. Life. 2024 May 24;14(6):672.
2. Chen J, Hu S, Sun M, Shi J, Zhang H, Yu H, Yang Z. Recent advances and clinical translation of liposomal delivery systems in cancer therapy. European Journal of Pharmaceutical Sciences. 2024 Feb 1;193:106688.
3. Andra VV, Pammi SV, Bhatraju LV, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience. 2022 Mar;12(1):274-91.
4. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.
5. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160.
6. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975-999.
7. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. Journal of Controlled Release, 111(1-2), 5-18.
8. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome-assisted drug delivery. Frontiers in Pharmacology, 6, 286.
9. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102.
10. Banerjee, R. (2001). Liposomes: Applications in medicine. Journal of Biomaterials Applications, 16(1), 3-21.
11. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003.
12. Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., & Bannerjee, S. K. (2012). Drug delivery systems: An updated review. International Journal of Pharmaceutical Investigation, 2(1), 2-11.
13. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123-140.
14. Aghila Rani, K.G.; Hamad, M.A.; Zaher, D.M.; Sieburth, S.M.; Madani, N.; Al-Tel, T.H. Drug development post COVID-19 pandemic: Toward a better system to meet current and future global health challenges. Expert. Opin. Drug Discov. 2021, 16, 365–371.
15. Gavas, S.; Quazi, S.; Karpiński, T.M. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res. Lett. 2021, 16, 173.
16. Giordani, S.; Marassi, V.; Zattoni, A.; Roda, B.; Reschiglian, P. Liposomes characterization for market approval as pharmaceutical products: Analytical methods, guidelines and standardized protocols. J. Pharm. Biomed. Anal. 2023, 236, 115751.
17. FDA. Drugs@FDA: FDA-Approved Drugs; FDA: White Oak, MD, USA, 2024.
18. Large, D.E.; Abdelmessih, R.G.; Fink, E.A.; Auguste, D.T. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 2021, 176, 113851.
19. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 102.
20. Nsairat, H.; Khater, D.; Sayed, U.; Odeh, F.; Al Bawab, A.; Alshaer, W. Liposomes: Structure, composition, types, and clinical applications. Heliyon 2022, 8, e09394.
21. Alavi, M.; Mozafari, M.R.; Hamblin, M.R.; Hamidi, M.; Hajimolaali, M.; Katouzian, I. Industrial-scale methods for the manufacture of liposomes and nanoliposomes: Pharmaceutical, cosmetic, and nutraceutical aspects. Micro. Nano Bio. Asp. 2022, 1, 26–35.
22. Briuglia, M.-L.; Rotella, C.; McFarlane, A.; Lamprou, D.A. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv. Transl. Res. 2015, 5, 231–242.
23. Nsairat, H.; Ibrahim, A.A.; Jaber, A.M.; Abdelghany, S.; Atwan, R.; Shalan, N.; Abdelnabi, H.; Odeh, F.; El-Tanani, M.; Alshaer, W. Liposome bilayer stability: Emphasis on cholesterol and its alternatives. J. Liposome Res. 2024, 34, 178–202.
24. Sun, J.; Zhang, L.; Wang, J.; Feng, Q.; Liu, D.; Yin, Q.; Xu, D.; Wei, Y.; Ding, B.; Shi, X.; et al. Tunable rigidity of (polymeric core)-(lipid shell)

*Corresponding Author: **Sanju**

nanoparticles for regulated cellular uptake. Adv. Mater. 2015, 27, 1402–1407.
25. Kabilova, T.O.; Shmendel, E.V.; Gadkikh, D.V.; Chernolovskaya, E.L.; Markov, O.V.; Morozova, N.G.; Maslov, M.A.; Zenkova, M.A. Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes. Eur. J. Pharm. Biopharm. 2018, 123, 59–70.
26. Patil, Y.; Amitay, Y.; Ohana, P.; Shmeeda, H.; Gabizon, A. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. J. Control. Release 2016, 225, 87–95.
27. Wang, L.; Evans, J.C.; Ahmed, L.; Allen, C. Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous
28. Meers, P.R.; Pak, C.; Ali, S.; Janoff, A.S.; Franklin, J.C.; Erukulla, R.K.; Cabral-Lilly, D.; Ahl, P.L. Peptide-Lipid Conjugates, Liposomes and Lipsomal Drug Delivery. U.S. Patent 6,339,069, 15 January 2002.

*Corresponding Author: **Sanju**